{
    "name": "gadodiamide",
    "comment": "Rx",
    "other_names": [
        "Omniscan"
    ],
    "classes": [
        "Contrast Media",
        "Nonionic/Low Osmolality",
        "Gadolinium-Containing Contrast Agents"
    ],
    "source": "https://reference.medscape.com/drug/omniscan-gadodiamide-343764",
    "pregnancy": {
        "common": [
            "GBCAs cross the placenta and result in fetal exposure and gadolinium retention",
            "Human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive",
            "Estimated background risk of major birth defects and miscarriage for the indicated population is unknown; because of potential risks of drug to fetus, use drug only if imaging is essential during pregnancy and cannot be delayed"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Drug has been shown to have adverse effect on embryo-fetal development in rabbits at dosages as low as 0.5 mmol/ kg/ day for 13 days during gestation (approximately 0.6 times human dose based on a body surface area comparison); these adverse effects are observed as an increased incidence of flexed appendages and skeletal malformations which may be due to maternal toxicity since body weight of dams was reduced in response to gadodiamide administration during pregnancy"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human milk, effects on breastfed infant or on milk production; estimated infant exposure is 0.001%-0.04% of the maternal dose",
            "Unknown whether the effects of the drug on the breastfed infant or the effects of the drug on milk production",
            "Developmental and health benefits of breastfeeding should be considered together with the mother’s clinical need for the drug and any potential adverse effects on the breastfed infant or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Not for intrathecal (IT) use; inadvertent IT administration has caused convulsions, coma, sensory and motor neurologic deficits"
            ],
            "specific": [
                {
                    "type": "Nephrogenic systemic fibrosis",
                    "description": [
                        "Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs",
                        "Avoid use of GBCAs in these patients unless diagnostic information is essential and not available with noncontrasted MRI or other modalities",
                        "NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs",
                        "Highest risk for NSF is among patients with chronic, severe kidney disease (GFR <30 mL/min/1.73²) OR acute kidney injury",
                        "Screen patients for acute kidney injury and other conditions that may reduce renal function",
                        "For patients at risk for chronically reduced renal function (eg, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing",
                        "For patients at highest risk for NSF, do not exceed recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to readministration"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Acute kidney disease or chronic, severe kidney disease (ie, GFR <30 mL/min/1.73m²); use associated with increased risk for nephrogenic systemic fibrosis (NSF)",
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Not for intrathecal use (see Black Box Warnings)",
                "Anemia, hepatic/renal impairment",
                "Acute renal failure has occurred in patients with pre-existing renal insufficiency; use the lowest necessary dose and evaluate renal function",
                "Nephrogenic systemic fibrosis (NSF) reported in patients with impaired elimination; higher than recommended dosing or repeat dosing appears to increase the risk",
                "Anaphylactoid and anaphylactic reactions with cardiovascular, respiratory and/or cutaneous manifestations, resulting in death have occurred"
            ],
            "specific": [
                {
                    "type": "Gadolinium retention",
                    "description": [
                        "Gadolinium is retained for months or years in several organs",
                        "Highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (eg, brain, skin, kidney, liver, and spleen)",
                        "Duration of retention also varies by tissue and is longest in bone",
                        "Patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions are at higher risk of gadolinium retention",
                        "Brain deposits",
                        "FDA investigated the risk of brain deposits following repeated use of GBCAs for MRI in 2015",
                        "Publications in the medical literature have reported that deposits of GBCAs remain in the brains of some patients who undergo ≥4 contrast MRI scans, long after the last administration",
                        "As of 2017, the FDA review had not identified adverse health effects from gadolinium retained in the brain after the use of GBCAs MRI; all GBCAs may be associated with some gadolinium retention in the brain and other body tissues",
                        "Early data in rat studies show that linear GBCAs are more prone to dissociation into free gadolinium and demonstrate greater brain deposition than macrocyclic GBCAs, which are less prone to dissociation"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Application site disorders",
            "percent": null
        },
        {
            "name": "Injection site reaction",
            "percent": null
        },
        {
            "name": "Autonomic nervous system disorders",
            "percent": null
        },
        {
            "name": "Vasodilation",
            "percent": null
        },
        {
            "name": "Body as a whole",
            "percent": null
        },
        {
            "name": "general disorders",
            "percent": null
        },
        {
            "name": "Anaphylactoid reactions",
            "percent": null
        },
        {
            "name": "characterized by cardiovascular",
            "percent": null
        },
        {
            "name": "respiratory",
            "percent": null
        },
        {
            "name": "and cutaneous symptoms",
            "percent": null
        },
        {
            "name": "fever",
            "percent": null
        },
        {
            "name": "hot flushes",
            "percent": null
        },
        {
            "name": "rigors",
            "percent": null
        },
        {
            "name": "fatigue",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "syncope",
            "percent": null
        },
        {
            "name": "Cardiovascular disorders",
            "percent": null
        },
        {
            "name": "Cardiac failure",
            "percent": null
        },
        {
            "name": "rare arrhythmia and myocardial infarction resulting in death in patients with ischemic heart disease",
            "percent": null
        },
        {
            "name": "flushing",
            "percent": null
        },
        {
            "name": "chest pain",
            "percent": null
        },
        {
            "name": "deep thrombophlebitis",
            "percent": null
        },
        {
            "name": "Central and peripheral nervous system disorders",
            "percent": null
        },
        {
            "name": "Convulsions including grand mal",
            "percent": null
        },
        {
            "name": "ataxia",
            "percent": null
        },
        {
            "name": "abnormal coordination",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "tremor",
            "percent": null
        },
        {
            "name": "aggravated multiple sclerosis",
            "percent": null
        },
        {
            "name": "characterized by sensory and motor disturbances",
            "percent": null
        },
        {
            "name": "aggravated migraine",
            "percent": null
        },
        {
            "name": "Gastrointestinal system disorders",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "eructation",
            "percent": null
        },
        {
            "name": "dry mouth",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "melena",
            "percent": null
        },
        {
            "name": "Hearing and vestibular disorders",
            "percent": null
        },
        {
            "name": "Tinnitus",
            "percent": null
        },
        {
            "name": "Liver and biliary system disorders",
            "percent": null
        },
        {
            "name": "Abnormal hepatic function",
            "percent": null
        },
        {
            "name": "Musculoskeletal system disorders",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "myalgia",
            "percent": null
        },
        {
            "name": "Respiratory system disorders",
            "percent": null
        },
        {
            "name": "Rhinitis",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "Skin and appendage disorders",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "erythematous rash",
            "percent": null
        },
        {
            "name": "sweating increased",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Special senses",
            "percent": null
        },
        {
            "name": "other disorders",
            "percent": null
        },
        {
            "name": "Taste loss",
            "percent": null
        },
        {
            "name": "taste perversion",
            "percent": null
        },
        {
            "name": "Urinary system disorders",
            "percent": null
        },
        {
            "name": "Acute reversible renal failure",
            "percent": null
        },
        {
            "name": "Vision disorders",
            "percent": null
        },
        {
            "name": "Abnormal vision",
            "percent": null
        }
    ]
}